Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Fei Yang, Nicola Long, Tauangtham Anekpuritanang, Daniel Bottomly, Jonathan C. Savage, Tiffany Lee, Jose Solis-Ruiz, Uma Borate, Beth Wilmot, Cristina Tognon, Allison M. Bock, Daniel A. Pollyea, Saikripa Radhakrishnan, Srinidhi Radhakrishnan, Prapti Patel, Robert H. Collins, Srinivas Tantravahi, Michael W. Deininger, Guang Fan, Brian DrukerUjwal Shinde, Jeffrey W. Tyner, Richard Press, Shannon McWeeney, Anupriya Agarwal

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Inherited predisposition to myeloid malignancies is more common than previously appreciated. We analyzed the whole-exome sequencing data of paired leukemia and skin biopsy samples from 391 adult patients from the Beat AML 1.0 consortium. Using the 2015 American College of Medical Genetics and Genomics (ACMG) guidelines for variant interpretation, we curated 1547 unique variants from 228 genes. The pathogenic/likely pathogenic (P/LP) germline variants were identified in 53 acute myeloid leukemia (AML) patients (13.6%) in 34 genes, including 6.39% (25/391) of patients harboring P/LP variants in genes considered clinically actionable (tier 1). 41.5% of the 53 patients with P/LP variants were in genes associated with the DNA damage response. The most frequently mutated genes were CHEK2 (8 patients) and DDX41 (7 patients). Pathogenic germline variants were also found in new candidate genes (DNAH5, DNAH9, DNMT3A, and SUZ12). No strong correlation was found between the germline mutational rate and age of AML onset. Among 49 patients who have a reported history of at least one family member affected with hematological malignancies, 6 patients harbored known P/LP germline variants and the remaining patients had at least one variant of uncertain significance, suggesting a need for further functional validation studies. Using CHEK2 as an example, we show that three-dimensional protein modeling can be one of the effective methodologies to prioritize variants of unknown significance for functional studies. Further, we evaluated an in silico approach that applies ACMG curation in an automated manner using the tool for assessment and (TAPES) prioritization in exome studies, which can minimize manual curation time for variants. Overall, our findings suggest a need to comprehensively understand the predisposition potential of many germline variants in order to enable closer monitoring for disease management and treatment interventions for affected patients and families.

Original languageEnglish (US)
Pages (from-to)1208-1221
Number of pages14
JournalBlood
Volume139
Issue number8
DOIs
StatePublished - Feb 24 2022

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML'. Together they form a unique fingerprint.

Cite this